Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 25:2018:18-0107.
doi: 10.1530/EDM-18-0107.

A novel CASR mutation (p.Glu757Lys) causing autosomal dominant hypocalcaemia type 1

Affiliations

A novel CASR mutation (p.Glu757Lys) causing autosomal dominant hypocalcaemia type 1

Benjamin Kwan et al. Endocrinol Diabetes Metab Case Rep. .

Abstract

Autosomal dominant hypocalcaemia type 1 (ADH1) is a rare familial disorder characterised by low serum calcium and low or inappropriately normal serum PTH. It is caused by activating CASR mutations, which produces a left-shift in the set point for extracellular calcium. We describe an Australian family with a novel heterozygous missense mutation in CASR causing ADH1. Mild neuromuscular symptoms (paraesthesia, carpopedal spasm) were present in most affected individuals and required treatment with calcium and calcitriol. Basal ganglia calcification was present in three out of four affected family members. This case highlights the importance of correctly identifying genetic causes of hypocalcaemia to allow for proper management and screening of family members. Learning points: •• ADH1 is a rare cause of hypoparathyroidism due to activating CASR mutations and is the mirror image of familial hypocalciuric hypercalcaemia. •• In patients with ADH1, symptoms of hypocalcaemia may be mild or absent. Basal ganglia calcification may be present in over a third of patients. •• CASR mutation analysis is required for diagnostic confirmation and to facilitate proper management, screening and genetic counselling of affected family members. •• Treatment with calcium and activated vitamin D analogues should be reserved for symptomatic individuals due to the risk of exacerbating hypercalciuria and its associated complications.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Family pedigree. The arrow indicates the proband. Filled symbols, individuals with hypocalcaemia; dotted symbols, status unknown; slash, deceased; E, CASR gene mutation analysis.

Similar articles

Cited by

References

    1. Pidasheva S, D’Souza-Li L, Canaff L, Cole DE, Hendy GN. CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Human Mutation 2004. 24 107–111. (10.1002/humu.20067) - DOI - PubMed
    1. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nature Methods 2010. 7 248–249. (10.1038/nmeth0410-248) - DOI - PMC - PubMed
    1. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nature Methods 2014. 11 361–362. (10.1038/nmeth.2890) - DOI - PubMed
    1. Conigrave AD. The calcium-sensing receptor and the parathyroid: past, present, future. Frontiers in Physiology 2016. 7 563 (10.3389/fphys.2016.00563) - DOI - PMC - PubMed
    1. Roszko KL, Bi RD, Mannstadt M. Autosomal dominant hypocalcemia (hypoparathyroidism) types 1 and 2. Frontiers in Physiology 2016. 7 458 (10.3389/fphys.2016.00458) - DOI - PMC - PubMed

LinkOut - more resources